Drug intelligence / Profile preview

AL 721

Development stage: Phase 1
Lead developer: Ethigen
Modality: Small Molecules
Administration: Oral

Overview

AL 721 is a lipid compound composed of neutral lipids, phosphatidylcholine, and phosphatidylethanolamine in a 7:2:1 ratio. It was investigated as a potential treatment for HIV infections based on its theorized mechanism of depleting cholesterol from cell membranes or viral particles, potentially inhibiting HIV infection. The compound was discovered at the Weizman Institute in Israel and developed by Ethigen Corporation.

Brand names: Altrigen

Beyond the preview

Go deeper on AL 721.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AL 721.

Explore the full profile